Brainsway Ltd. American Depositary Shares (BWAY) Stock Price
BWAYStock
$11.44+153.31%52W
Market Cap$460.49M
P/E61.33x
PEG Ratio—
Div yield—
Beta0.96
BWAY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-24.78%
Price vs S&P 500 (4W)-7.46%
VGM Score56.89
P/E Ratio (Annual)61.33x
BWAY Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.07 | $0.07 | -4.54%(-$0.00) | |
| Q1 2026 | $0.05 | $0.06 | +20.00%(+$0.01) | |
| Q4 2025 | $0.03 | $0.06 | +155.36%(+$0.04) | |
| Q3 2025 | $0.02 | $0.02 | -14.27%(-$0.00) | |
| Q2 2025 | $0.02 | $0.03 | +53.85%(+$0.01) |
BWAY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.29
4.29
4.29
4.29
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BWAYBrainsway Ltd. American Depositary Shares | D | B | B | 9.5x | 12.2% | 74.9% | 5.8% | $11.44 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Brainsway Ltd. American Depositary Shares
BrainsWay Ltd develops Deep Transcranial Magnetic Stimulation (Deep TMS), a noninvasive neurostimulation platform for treating mental health and neurological disorders. The company currently generates revenue through lease and sale of Deep TMS systems for FDA-approved indications including major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Additional clinical trials are underway to expand the platform's therapeutic applications across psychiatric, neurological, and addiction disorders.